Soligenix awarded $26.3 million contract
The contract is for the preclinical and manufacturing development of OrbeShield, a biodefense medical countermeasure for the treatment of gastrointestinal acute radiation syndrome. The contract is set for two years, with the option of a three year extension. The total contract will aid the successful completion of the development and manufacturing process for OrbeShield to gain approval from the U.S. Food and Drug Administration.
"Securing a highly competitive BARDA contract provides important recognition as to the innovative quality and potential therapeutic impact of our technology," President and Chief Executive Officer of Soligenix Christopher J. Schaber said. "This contract award provides the comprehensive funding necessary to continue development of OrbeShield while building upon the growing body of compelling scientific evidence supporting its use as a potential MCM for GI ARS. We thank BARDA for their support and look forward to collaborating closely with them as we advance this technology."
Soligenix is a clinical stage biopharmaceutical company that focuses on the development of drugs to fight inflammatory diseases and MCMs, for which there is an unmet medical need.